• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sanofi (Amendment)

    2/15/22 8:17:33 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email
    SC 13G/A 1 sanofi12312021.htm SCHEDULE 13G
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO. 1 )*

    Name of issuer:  Sanofi

    Title of Class of Securities:  Common Stock

    CUSIP Number:  Not Applicable**

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    ** The CUSIP number is not applicable. The Reporting Persons hold common stock with ISIN FR0000120578.


    1.  NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Amundi

    2.  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)☐
    (b)☐

    3.  SEC USE ONLY

    4.  CITIZENSHIP OR PLACE OF ORGANIZATION

    Republic of France

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    28,542,929

    7.  SOLE DISPOSITIVE POWER

    0

    8.  SHARED DISPOSITIVE POWER

    47,563,237

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    47,563,237

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    ☐ Not Applicable

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.8%

    12.  TYPE OF REPORTING PERSON

    HC


    1.  NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Amundi Asset Management

    2.  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)☐
    (b)☐

    3.  SEC USE ONLY

    4.  CITIZENSHIP OR PLACE OF ORGANIZATION

    Republic of France

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    28,542,929

    7.  SOLE DISPOSITIVE POWER

    0

    8.  SHARED DISPOSITIVE POWER

    47,563,237

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    47,563,237

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    ☐ Not Applicable

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.8%

    12.  TYPE OF REPORTING PERSON

    FI


    Item 1(a) - Name of Issuer:

    Sanofi

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    54 RUE LA BOETIE
    PARIS I0 75008

    Item 2(a) - Name of Person Filing:

    Amundi
    Amundi Asset Management

    Item 2(b) – Address of Principal Business Office or, if none, Residence:

    Amundi
    91-93 boulevard Pasteur
    75015 Paris, France

    Amundi Asset Management
    90 boulevard Pasteur
    75015 Paris, France

    Item 2(c) – Citizenship:

    Both Amundi and Amundi Asset Management are organized under the laws of the Republic of France.

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    The CUSIP number is not applicable. The Reporting Persons hold common stock with ISIN FR0000120578.

    Item 3 - If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ☑ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);
    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of
    institution: ____________________________ .

    Item 4 - Ownership:
    Amundi is a majority-owned affiliate of Credit Agricole S.A., a French bank. Amundi Asset Management is a wholly-owned subsidiary of Amundi.

    (a) Amount beneficially owned: See Item 9 of each cover page.
    (b) Percent of class: See Item 11 of each cover page.
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: See Item 5 of each cover page.
    (ii) Shared power to vote or to direct the vote: See Item 6 of each cover page.
    (iii) Sole power to dispose or to direct the disposition of: See Item 7 of each cover page.
    (iv) Shared power to dispose or to direct the disposition of: See Item 8 of each cover page.
     
    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☑

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not Applicable

    Item 9 - Notice of Dissolution of Group:

    Not Applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: Executed as a sealed instrument this 14th day of February, 2022.

    Company Name
    Amundi
    By: /s/ Lisa M. Jones
    Name: Lisa M. Jones
    Title: President and Chief Executive Officer
    Head of the Americas
    Amundi US, Inc.
    By Power of Attorney

    Company Name
    Amundi Asset Management
    By: /s/ Lisa M. Jones
    Name: Lisa M. Jones
    Title: President and Chief Executive Officer
    Head of the Americas
    Amundi US, Inc.
    By Power of Attorney


    AGREEMENT

    Each of the undersigned, pursuant to Rule 13d-1(k)(l) under the Securities Exchange Act of 1934, as amended, hereby agrees that only one statement containing the information required by Schedule 13G needs be filed with respect to the ownership by each of the undersigned of the shares of common stock of Sanofi that the Schedule 13G to which this Agreement is appended as Exhibit 1 is to be filed with the Securities and Exchange Commission on behalf of each of the undersigned on or about the date hereof.

    EXECUTED as a sealed instrument this 14th day of February, 2022.

    Company Name
    Amundi
    By: /s/ Lisa M. Jones
    Name: Lisa M. Jones
    Title: President and Chief Executive Officer
    Head of the Americas
    Amundi US, Inc.
    By Power of Attorney

    Company Name
    Amundi Asset Management
    By: /s/ Lisa M. Jones
    Name: Lisa M. Jones
    Title: President and Chief Executive Officer
    Head of the Americas
    Amundi US, Inc.
    By Power of Attorney


    Appendix A

    Subsidiary:

    AMUNDI AALAM SDN BHD
    Amundi Asset Management
    AMUNDI ASSET MANAGEMENT US INC
    Amundi Austria GmbH
    Amundi Canada Inc.
    Amundi Czech Republic Asset Management
    Amundi Czech Republic Investicni Spolecnost, A.S.
    Amundi Deutschland GmbH
    Amundi Hong-Kong Ltd
    Amundi Iberia SGIIC, SA
    AMUNDI IRELAND LIMITED
    Amundi Japan Ltd
    Amundi Luxembourg SA
    Amundi SGR SpA
    Amundi Singapore Ltd
    Amundi UK Ltd
    BFT Investment Managers
    CPR AM
    Etoile Gestion
    KBI
    LYXOR ASSET MANAGEMENT S.A.S.
    LYXOR FUNDS SOLUTIONS S.A.
    Lyxor International Asset Management S.A.S.
    NH-Amundi Asset Management Co. Ltd
    SABADELL ASSET MANAGEMENT S.A. S.G.I.I.C. S.U.
    Societe Generale Gestion



    Get the next $SNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    3/21/2025$65.00Neutral
    Goldman
    1/30/2025Sell → Hold
    Deutsche Bank
    7/26/2024$55.00 → $60.00Buy
    Argus
    1/23/2024$55.00Equal-Weight
    Morgan Stanley
    1/16/2024Buy
    UBS
    12/5/2023Overweight → Neutral
    JP Morgan
    10/30/2023Buy → Hold
    Stifel
    More analyst ratings

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

      Believes Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA

      4/21/25 4:05:00 PM ET
      $DVAX
      $MRNA
      $SNY
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement

      Teigen to advocate for the importance of type 1 diabetes screening after son's diagnosis was uncovered during an unexpected medical emergencyScreen For Type 1 movement continues momentum into year two with the goal of encouraging people to screen early; just one blood test can spot type 1 diabetes before symptoms occurMORRISTOWN, N.J., April 15, 2025 /PRNewswire/ -- Sanofi, a leader in diabetes care, welcomes author, entrepreneur, and mom Chrissy Teigen as its new celebrity spokesperson for the Screen For Type 1 movement. The partnership, announced on T1D Day, comes as the Screen For Type 1 movement strives to expand diabetes education nationwide, raising awareness of the benefits of early r

      4/15/25 8:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

      BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications. Sanofi plans to begin shipping flu vaccines this summer so that health systems, hospitals, pharm

      3/14/25 2:18:00 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

      For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

      3/28/25 10:17:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

      For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

      2/14/25 3:00:13 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

      Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

      11/4/24 4:49:34 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Financials

    Live finance-specific insights

    See more
    • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

      ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, toda

      5/13/24 7:00:00 AM ET
      $FULC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

      ― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today to discuss the collaboration and other recent corporate developments, in conjunction with the first quarter 2024 financial results ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a c

      5/13/24 6:00:00 AM ET
      $FULC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

      Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:$500 million upfront payment Approximately $70 million equity investment in NovavaxUp to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to P

      5/10/24 2:15:00 AM ET
      $NVAX
      $SNY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $SNY
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi Bridging the Gap between the Homeless and Society via Futsal

      Sanofi hosted the founding ceremony of the homeless futsal club ‘Dream' and organized a friendly match as a part of the Helping Hands program Sanofi employees and ‘Dream' members interacted through the friendly match Sanofi has carried out social responsibility activities targeting the homeless and housing vulnerable groups since 2011 Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream' together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless. At the founding ceremony of the ‘Dream', held in Seongsu-dong, Seoul on the 17th, the club's first game

      10/17/23 9:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

      BRIDGEWATER, N.J., Aug. 3, 2022 /PRNewswire/ -- Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses. Olivier Bogillot becomes Head of U.S. General Medicines. Bogillot, most recently President of Sanofi France, will lead the business unit responsible for serving the Diabetes, Cardiovascular and Transplant communities effective September 1. Bogillot joined Sanofi in 2015, and has held various positions within the company, including as Executive Director of Global Policy based in the U.S. and Chief of Staff to the CEO. In March 2020, he was appointed President of Sanofi France, where he has led

      8/3/22 2:53:00 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

      4 - Sanofi (0001121404) (Reporting)

      8/2/21 8:34:24 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by Sanofi

      3 - Sanofi (0001121404) (Reporting)

      7/28/21 8:32:04 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sanofi

      SC 13G/A - Sanofi (0001121404) (Subject)

      11/7/24 2:49:36 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sanofi

      SC 13G - Sanofi (0001121404) (Filed by)

      5/31/24 4:30:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sanofi (Amendment)

      SC 13G/A - Sanofi (0001121404) (Subject)

      2/14/24 3:57:49 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    SEC Filings

    See more
    • SEC Form 13F-HR filed by Sanofi

      13F-HR - Sanofi (0001121404) (Filer)

      5/6/25 6:15:02 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      5/5/25 1:12:12 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      4/30/25 2:50:47 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on Sanofi with a new price target

      Exane BNP Paribas initiated coverage of Sanofi with a rating of Outperform and set a new price target of $65.00

      4/15/25 12:40:46 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Sanofi with a new price target

      Goldman initiated coverage of Sanofi with a rating of Neutral and set a new price target of $65.00

      3/21/25 8:12:02 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi upgraded by Deutsche Bank

      Deutsche Bank upgraded Sanofi from Sell to Hold

      1/30/25 3:33:45 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care